THE US Food and Drug Administration (FDA) has made available a panel of human plasma samples to aid in the regulatory evaluation of serological tests to detect recent Zika virus infection.
The panel includes de-identified samples from individuals infected with Zika, West Nile or Dengue viruses, and is available to developers with devices in the final stages of validation.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Aug 17
